Myelodysplastic syndromes: trials for referral
396 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
396 trials shown
Phase 21 site
RecruitingUnited States
NCT03589729
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Pre-treatment window Registry sentence: “Patients with untreated or previously untreated chronic myeloid leukemia (CML) in myeloid blast phase or (Philadelphia chromosome-positive (Ph+) AML are also eligible.”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07738510
A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions
Halia Therapeutics, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT06303193
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
National Cancer Institute (NCI)
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 111 sites
Not yet recruitingSpain, France, Italy
NCT07929740
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Kura Oncology, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingUnited States
NCT04986657
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Washington University School of Medicine
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT06523556
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Uma Borate
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 2227 sites
RecruitingCanada, Puerto Rico, United States
NCT05554406
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per World Health Organization (WHO) criteria”
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 22 sites
RecruitingUnited States
NCT01174108
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
National Heart, Lung, and Blood Institute (NHLBI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06996119
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 1/213 sites
RecruitingUnited States
NCT05308264
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Rigel Pharmaceuticals
Pre-treatment window Registry sentence: “No prior therapy with any approved or investigational therapies for MDS”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07617363
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Washington University School of Medicine
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3182 sites
RecruitingAustralia, Bulgaria, Brazil, Canada, Switzerland, Chile
NCT06499285
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3165 sites
RecruitingArgentina, Australia, Belgium, Bulgaria, Brazil, Switzerland
NCT07422480
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Takeda
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07468916
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 2151 sites
RecruitingPuerto Rico, United States
NCT06577441
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “REGISTRATION ELIGIBILITY CRITERIA (STEP 1): No prior treatment with deoxyribonucleic acid (DNA) methyltransferase inhibitors (ASTX727, azacitidine, or decitabine).”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 142 sites
By invitation onlyAustralia, Belgium, Denmark, Spain, France, United Kingdom
NCT06788509
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 111 sites
RecruitingDenmark, Spain, Italy, Netherlands
NCT07384715
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Genmab
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 123 sites
RecruitingUnited States
NCT06484062
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “In Cohort III, patients must have prior untreated high-risk MDS”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 387 sites
RecruitingAustria, Belgium, Germany, Estonia, Finland, Lithuania
NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Pre-treatment window Registry sentence: “No prior chemotherapy for AML, except hydroxyurea for up to 14 days during the diagnostic screening phase for the control of peripheral leukemic blasts in patients with leukocytosis (e.g., white blood cell \[WBC\] counts \> 25x109/L); patients may have had previous treatment with erythroid stimulating agents (ESA) or hypomethylating agents (HMAs) for an antecedent phase of MDS; ESA and HMAs have to be stopped at least four weeks before start of study treatment.”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 13 sites
RecruitingUnited Kingdom, United States
NCT07723703
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
Amphista Therapeutics Ltd
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT03520647
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
National Heart, Lung, and Blood Institute (NHLBI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Cancer Institute (NCI)
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT02727803
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT03214562
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07909733
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
University of Wisconsin, Madison
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06287944
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07758218
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
University of Wisconsin, Madison
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT06265584
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 19 sites
RecruitingFrance, United States
NCT06297941
Study of REM-422 in Patients With AML or Higher Risk MDS
Remix Therapeutics
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07254793
Prophylactic DLI-X for Leukemia Relapse After HCT
University of Arizona
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States224 open trials
- China52 open trials
- France50 open trials
- Spain31 open trials
- Italy28 open trials
- Germany28 open trials
- United Kingdom22 open trials
- Canada20 open trials
- Australia17 open trials
- Poland15 open trials
- Belgium12 open trials
- South Korea10 open trials
- Denmark10 open trials
- Sweden9 open trials
- Japan9 open trials
- Czechia7 open trials
- Bulgaria7 open trials
- Norway7 open trials
- Greece7 open trials
- Netherlands7 open trials
- Israel6 open trials
- Finland6 open trials
- Switzerland5 open trials
- Taiwan5 open trials
- Lithuania5 open trials
- Russia5 open trials
- Hungary4 open trials
- Brazil4 open trials
- Romania4 open trials
- Austria4 open trials
- New Zealand4 open trials
- Thailand3 open trials
- Türkiye3 open trials
- Puerto Rico3 open trials
- Armenia3 open trials
- Slovakia3 open trials
- Ireland2 open trials
- India2 open trials
- Malaysia2 open trials
- Singapore2 open trials
- Chile1 open trial
- South Africa1 open trial
- Argentina1 open trial
- Moldova1 open trial
- Ukraine1 open trial
- Georgia1 open trial
- Estonia1 open trial
- Hong Kong1 open trial
- Monaco1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
8 trials · 9 publications · ROR
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
13 trials · 7 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
Status changed: Running, not recruiting → Completed
NCT07052006 · Phase 2 · India
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07214064 · Phase 2 · Germany
Source: ClinicalTrials.govStatus changed: Recruiting → By invitation only
NCT06987058 · Phase 2 · Spain, France, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 · Phase 2 · Italy
Source: ClinicalTrials.govOpened for recruitment
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606 · Phase 1 · France, United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT06602323 · Phase 2 · Spain
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
NCT06533761 · Phase 1 · Spain, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT06359002 · Phase 1 · Belgium, Spain, Netherlands
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458 · Phase 2 · Germany, Spain, France, Italy, Poland
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT05673057 · Phase 1 · Switzerland, France, Lithuania, Netherlands
Source: ClinicalTrials.govClosed for recruitment
NCT05469737 · Phase 2/3 · Argentina, Austria, Australia, Canada, China, Czechia
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05428969 · Phase 1/2 · Finland, United Kingdom, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05490446 · Phase 2 · Austria, Australia, Czechia, Germany, Spain, France
Source: ClinicalTrials.govOpened for recruitment
NCT04953910 · Phase 1 · Armenia, Bulgaria, Spain, Lithuania, Poland, Romania
Source: ClinicalTrials.govOpened for recruitment
NCT04419649 · Phase 2 · Australia, Czechia, Germany, Spain, France, Israel
Source: ClinicalTrials.govPhase changed: Phase 3 → Phase 2/3
NCT04256317 · Phase 2/3 · Canada, Czechia, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govOpened for recruitment
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570 · Phase 2 · Armenia, Austria, Bulgaria, Canada, Germany, Spain
Source: ClinicalTrials.govPhase changed: Phase 2 → Phase 3
NCT04027309 · Phase 3 · Austria, Australia, Belgium, Switzerland, Germany, Spain
Source: ClinicalTrials.govOpened for recruitment
NCT03850574 · Phase 1/2 · Australia, Germany, Spain, South Korea, New Zealand, Poland
Source: ClinicalTrials.gov
Show more
Phase changed: Phase 1 → Phase 1/2
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
NCT03502668 · Phase 1/2 · Belgium, Canada, Germany, Spain, Italy, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT02598661 · Phase 2/3 · Belgium, Canada, Switzerland, Czechia, Germany, Spain
Source: ClinicalTrials.govOpened for recruitment
NCT05469737 · Phase 2/3 · Argentina, Austria, Australia, Canada, China, Czechia
Source: ClinicalTrials.govClosed for recruitment
NCT04953910 · Phase 1 · Armenia, Bulgaria, Spain, Lithuania, Poland, Romania
Source: ClinicalTrials.govClosed for recruitment
NCT04419649 · Phase 2 · Australia, Czechia, Germany, Spain, France, Israel
Source: ClinicalTrials.govClosed for recruitment
NCT03850574 · Phase 1/2 · Australia, Germany, Spain, South Korea, New Zealand, Poland
Source: ClinicalTrials.govClosed for recruitment
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606 · Phase 1 · France, United States
Source: ClinicalTrials.govClosed for recruitment
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570 · Phase 2 · Armenia, Austria, Bulgaria, Canada, Germany, Spain
Source: ClinicalTrials.govClosed for recruitment
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
NCT06892223 · Phase 2 · Italy
Source: ClinicalTrials.govOpened for recruitment
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
NCT07752121 · No phase · Germany
Source: ClinicalTrials.govStopped early
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
NCT02530034 · Phase 1 · United States
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 15 Oct 2026
Stopped early15 participants
NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given: FDA Clinical Hold
No phaseEnded 30 Sept 2026
Completed307 participants
NCT04635384
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
Phase 2Ended 30 Sept 2026
Completed37 participants
NCT07052006
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
Phase 1Ended 14 Sept 2026
Completed80 participants
NCT05673057
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
No phaseEnded 10 Sept 2026
Completed11 participants
NCT04859218
Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?
Phase 1Ended 4 Sept 2026
Completed8 participants
NCT07444268
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
Phase 1Ended 1 Sept 2026
Completed64 participants
NCT06618001
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Phase 1Ended 28 Aug 2026
Stopped early34 participants
NCT06419634
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Reason given: Inability to meet protocol objectives
Phase 1/2Ended 14 Aug 2026
Stopped early58 participants
NCT02392572
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Reason given: \<75% participants
Phase 1/2Ended 11 Aug 2026
Completed7 participants
2025-520786-44-00
A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms
Phase 1Ended 6 Aug 2026
Completed35 participants
2024-519537-29-00
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
Phase 2Ended 17 Jul 2026
Phase 2Ended 16 Jul 2026
Stopped early23 participants
NCT04994808
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Reason given: The study was closed due to the end of funding.
Phase 1Ended Jun 2026
Completed30 participants
NCT02494167
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Phase 2Ended 11 Jun 2026
Withdrawn before start0 participants
NCT06597734
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Reason given: PI request
Phase 1Ended 1 Jun 2026
Withdrawn before start0 participants
NCT03939585
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given: Lack of funding
No phaseEnded May 2026
Completed98 participants
NCT02323867
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
Phase 1/2Ended 29 May 2026
Stopped early34 participants
NCT04550442
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Reason given: \<75% participation
Phase 2Ended 27 May 2026
No phaseEnded 14 May 2026
Stopped early200 participants
NCT01962636
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given: No longer a research question to answer.
Show more
No phaseEnded 12 May 2026
Completed88 participants
NCT07073690
Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
Phase 1Ended 8 May 2026
Completed6 participants
NCT05564650
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Phase 3Ended 29 Apr 2026
Completed326 participants
NCT04173533
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
Phase 2Ended 16 Apr 2026
Completed21 participants
NCT04269213
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Phase 1Ended 15 Apr 2026
Completed134 participants
NCT02942290
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Phase 2Ended 8 Apr 2026
Completed30 participants
NCT04477850
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions
Phase 1Ended 24 Mar 2026
Stopped early3 participants
NCT06021600
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Reason given: Slow participant enrollment
Phase 2Ended 5 Mar 2026
Stopped early235 participants
NCT03404193
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Reason given: \<75% participation
Phase 2Ended 28 Feb 2026
Completed30 participants
NCT04103879
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Phase 1Ended 24 Feb 2026
Completed14 participants
NCT06179511
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.
No phaseEnded 24 Feb 2026
Phase 2Ended 23 Feb 2026
Completed8 participants
NCT07582991
Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome
Phase 1Ended 14 Feb 2026
Withdrawn before start0 participants
NCT05823480
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
Reason given: Withdrawn -ctms
Phase 1/2Ended 3 Feb 2026
Stopped early51 participants
NCT04160052
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Reason given: \<75% participation
Phase 2Ended 2 Feb 2026
No phaseEnded 1 Feb 2026
Phase 1Ended 21 Jan 2026
Completed86 participants
NCT05665530
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Phase 2Ended 20 Jan 2026
Completed121 participants
NCT01787487
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. · Journal of hematology & oncology, 2026
Phase 1Ended 20 Jan 2026
Completed18 participants
2024-517381-42-00
Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM
Phase 1/2Ended 13 Jan 2026
Completed160 participants
NCT03502668
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
Phase 1Ended 7 Jan 2026
Completed25 participants
NCT03232268
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
Phase 2Ended 4 Jan 2026
Withdrawn before start0 participants
NCT05927012
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Reason given: Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.
Phase 1/2Ended Dec 2025
Withdrawn before start0 participants
NCT05895201
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Reason given: PI has left IU with no plan to initiate study at IU
Phase 2Ended 31 Dec 2025
Completed48 participants
2024-515352-20-00
Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1
Phase 1Ended 31 Dec 2025
No phaseEnded 31 Dec 2025
Completed2115 participants
NCT02775383
The National Myelodysplastic Syndromes (MDS) Study
- Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex. · American journal of hematology, 2026
- A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study. · Blood advances, 2026
Phase 1Ended 19 Dec 2025
Phase 1/2Ended Nov 2025
Withdrawn before start0 participants
NCT05246384
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Reason given: Change in development plan
Phase 2Ended 27 Nov 2025
Completed33 participants
2023-509092-16-00
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
Phase 1Ended 4 Nov 2025
Phase 2Ended 1 Nov 2025
Stopped early10 participants
NCT04823624
MBG453 in Lower Risk MDS
Reason given: The trial closed early due to changes in support for the study drug.
Phase 1Ended 24 Oct 2025
Stopped early25 participants
NCT04937166
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Reason given: Slow enrolment
No phaseEnded 23 Oct 2025
Completed113 participants
NCT06143839
VYxeoS Liposomal Italian Observational Study iN the Real Practice
Phase 1Ended 23 Oct 2025
Completed30 participants
2024-517377-24-00
Cardiac safety of treosulfan chemotherapy prior to stem cell transplantation in patients with leukemia.
Phase 3Ended 17 Oct 2025
Completed21 participants
NCT03480360
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Phase 1/2Ended 13 Oct 2025
Completed54 participants
NCT06563804
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML
Phase 2Ended 9 Oct 2025
Phase 2Ended 30 Sept 2025
Completed46 participants
NCT05583552
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
No phaseEnded 30 Sept 2025
Phase 1Ended 25 Sept 2025
Completed114 participants
NCT03573310
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Not medical advice. fetched 11 Nov 2026